2018 Annual Meeting of Stockholders

Outstanding Equity Awards at Fiscal Year-end 2017

The following table summarizes the outstanding equity awards of the named executives as of December 31, 2017.

Name   Option Awards(1)   Stock Awards(2)
Option
Grant Date
  Number of
Securities
Underlying
Unexercised
Options (#)
Exercisable(3)
  Number of
Securities
Underlying
Unexercised
Options (#)
Unexercisable(3)
  Option
Exercise
Price
($)
  Option
Expiration
Date
Stock Award
Grant Date
  Number
of Shares
or Units
of Stock
That Have
Not Vested
(#)(4)
  Market
Value of
Shares or
Units of
Stock
That Have
Not Vested
($)(5)
  Equity
Incentive
Plan
Awards:
Number of
Unearned
Shares,
Units, or
Other
Rights
that Have
Not Vested
(#)(6)
  Equity
Incentive
Plan
Awards:
Market or
Payout
Value of
Unearned
Shares,
Units,
or Other
Rights that
Have Not
Vested
($)(5)
Mr. Wilson   02/22/2011   447,808   0   31.74   02/22/2021                    
  02/21/2012   444,060   0   31.56   02/21/2022                    
  02/12/2013   363,409   0   45.61   02/12/2023                    
  02/18/2014   309,237   0   52.18   02/18/2024                    
  02/18/2015   196,329   98,165   70.71   02/18/2025   02/18/2015   53,780   5,631,304        
  02/11/2016   98,441   196,883   62.32   02/11/2026   02/11/2016           173,300   18,146,243
  02/09/2017   0   248,447   78.35   02/09/2027   02/09/2017           137,844   14,433,645
Mr. Shebik         02/21/2012   26,446   0   31.56   02/21/2022                    
  03/06/2012   35,014   0   31.00   03/06/2022                    
  02/12/2013   75,188   0   45.61   02/12/2023                    
  02/18/2014   72,289   0   52.18   02/18/2024                    
  02/18/2015   48,015   24,008   70.71   02/18/2025   02/18/2015   13,153   1,377,251        
  02/11/2016   30,079   60,159   62.32   02/11/2026   02/11/2016           52,952   5,544,604
  02/09/2017   0   91,787   78.35   02/09/2027   02/09/2017           50,926   5,332,461
Mr. Civgin       02/12/2013   21,930   0   45.61   02/12/2023                    
  02/18/2014   84,337   0   52.18   02/18/2024                    
  02/18/2015   50,917   25,459   70.71   02/18/2025   02/18/2015   13,948   1,460,495        
  02/11/2016   26,251   52,502   62.32   02/11/2026   02/11/2016           46,214   4,839,068
  02/09/2017   0   64,596   78.35   02/09/2027   02/09/2017           35,840   3,752,806
Mr. Dugenske    03/03/2017   0   57,540   81.86   03/03/2027   03/03/2017           31,884   3,338,574
                      04/05/2017   49,128   5,144,193        
Mr. Winter       02/12/2013   105,994   0   45.61   02/12/2023                    
  02/18/2014   105,422   0   52.18   02/18/2024                    
  02/18/2015   66,154   33,078   70.71   02/18/2025   02/18/2015   18,122   1,897,555        
  02/11/2016   35,001   70,003   62.32   02/11/2026   02/11/2016           61,618   6,452,021
  02/09/2017   0   85,404   78.35   02/09/2027   02/09/2017           47,384   4,961,579
  1. The options granted in 2014 and after vest over three years: one-third will become exercisable on the anniversary of the grant date for each of the three years. The options granted in 2012 and 2013 vest over four years: 50% on the second anniversary date and 25% on each of the third and fourth anniversary dates. The other options vest in four installments of 25% on each of the first four anniversaries of the grant date. The exercise price of each option is equal to the closing price of Allstate’s common stock on the grant date. If there was no sale on the grant date, the closing price is calculated as of the last previous day on which there was a sale.

  2. The awards listed in this table are PSAs, except for Mr. Dugenske’s sign-on award of 49,128 restricted stock units in 2017. Each restricted stock unit represents the right to receive, without the payment of any consideration, one share of Allstate common stock on the conversion date, which is April 5, 2020.

  3. The aggregate value and aggregate number of exercisable and unexercisable in-the-money options as of December 31, 2017, for each of the named executives are as follows:

      Exercisable Unexercisable
    Name Aggregate
    Number
    (#)
    Aggregate
    Value
    ($)
    Aggregate
    Number
    (#)
    Aggregate
    Value
    ($)
    Mr. Wilson 1,859,284 113,729,331 543,495 18,232,543
    Mr. Shebik 287,031 15,663,918 175,954 5,785,917
    Mr. Civgin 183,435 8,570,244 142,557 4,793,917
    Mr. Dugenske 0 0 57,540 1,314,789
    Mr. Winter 312,571 15,534,991 188,485 6,343,328
  4. The PSAs vest in one installment on the day before the third anniversary of the grant date.

  5. Amount is based on the closing price of our common stock of $104.71 on December 29, 2017.

  6. The PSAs vest in one installment on the day before the third anniversary of the grant date. The number of shares that ultimately vest may range from 0 to 200% of the target depending on actual performance during the three-year performance period. For a description of the PSA program and the performance measures used, see pages 41-43 and 48. The number of PSAs reflected in this column for the 2016 and 2017 awards is the number of shares that would vest if the maximum level of performance is achieved. Final payouts under the PSAs will not be known until the respective performance period is completed.